FCGRT and myasthenia gravis: In several autoimmune diseases, including generalized myasthenia gravis (MG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP), blockade of FcRn results in a reduction of IgG autoantibodies and in clinical improvement of the patients (18–21).